A nurse is caring for a client who is prescribed a selegiline transdermal patch. Which of the following manifestations should the nurse anticipate the prescription will improve?

A. Depression: Selegiline transdermal patches are indicated for the treatment of major depressive disorder. As a selective monoamine oxidase-B (MAO-B) inhibitor, it increases the availability of neurotransmitters such as dopamine, which can improve depressive symptoms in adults. B. Anxiety: While selegiline may have indirect effects on mood, it is not primarily indicated for treating anxiety disorders. Anxiety may require other pharmacologic or therapeutic interventions specifically targeted to anxiety symptoms. C. Tardive dyskinesia: Tardive dyskinesia is a movement disorder often associated with long-term antipsychotic use. Selegiline does not treat or prevent tardive dyskinesia; it is not indicated for movement disorder management in this context. D. Bipolar mania: Selegiline is not indicated for the management of bipolar disorder or acute manic episodes. Treating mania typically involves mood stabilizers or antipsychotics rather than MAO-B inhibitors.